Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
4502 | Tokyo | JPY | Delayed | |
TAK | NYSE | USD | Real-time | |
TKPHF | OTC Markets | USD | Delayed | |
4502 | TradeGate | EUR | Delayed | |
4502 | Frankfurt | EUR | Delayed | |
TKD | Vienna | EUR | Real-time |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Christophe Weber | 56 | 2014 | President, CEO & Representative Director |
Masami Iijima | 72 | 2021 | Independent External Chair |
Ian T. Clark | 63 | 2019 | Independent External Director |
Constantine Saroukos | 53 | 2018 | Representative Director |
Andrew S. Plump | 59 | 2015 | President of Research & Development and Representative Director |
Michel Orsinger | 67 | 2016 | Independent External Director |
Jean-Luc Butel | 68 | 2019 | Independent External Director |
Koji Hatsukawa | 73 | 2016 | Independent External Director |
Yoshiaki Fujimori | 73 | 2016 | Independent External Director |
Emiko Higashi | 66 | 2016 | Independent External Director |
Steven S. Gillis | 71 | 2019 | Independent External Director |
Kimberly A. Reed | 53 | 2022 | Independent External Director |
Miki Tsusaka | 61 | 2023 | Independent External Director |
John M. Maraganore | 62 | 2022 | Independent External Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review